STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Teladoc (TDOC) Form 144 shows insider sale of 4,700 vested shares for $35,650.91

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Teladoc Health, Inc. (TDOC) Form 144 summary: This notice reports a proposed sale of 4,700 common shares through Fidelity Brokerage Services with an aggregate market value of $35,650.91, to be executed approximately on 09/02/2025 on the NYSE. The shares were acquired on 08/29/2025 as restricted stock vesting and were paid as compensation. The filing also discloses a prior sale by the same account: 4,653 shares sold on 06/02/2025 for $31,919.58. The filing includes the total number of shares outstanding reported as 176,690,662 and contains the required certification that the seller is not aware of undisclosed material adverse information.

Positive

  • Complete disclosure of proposed sale details including broker, share count, aggregate market value, and exchange
  • Acquisition method stated as restricted stock vesting and payment classified as compensation, improving transparency
  • Prior sale disclosed (4,653 shares for $31,919.58), showing historical continuity in filings

Negative

  • None.

Insights

TL;DR: Routine insider disposition filing; small number of shares relative to outstanding common stock suggests limited market impact.

The Form 144 documents a proposed sale of 4,700 shares acquired via restricted stock vesting and marked as compensation, with an approximate market value of $35,650.91. The filing follows a prior sale of 4,653 shares that yielded $31,919.58. For investors, this type of disclosure signals an insider selling vested compensation rather than an operational development. The magnitude disclosed is small in absolute dollar terms and compared to the stated 176,690,662 shares outstanding, indicating low direct impact on float or liquidity.

TL;DR: Filing meets Rule 144 disclosure obligations; provides transparency on insider compensation-derived sales.

The notice identifies the broker, sale timing, acquisition method (restricted stock vesting) and prior disposals, and includes the standard insider certification about material nonpublic information. This is a routine compliance disclosure that documents an insider monetizing vested equity awarded as compensation. The record of both the proposed sale and the earlier June sale is consistent with required transparency under securities rules.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TDOC Form 144 disclose about the proposed sale?

It reports a proposed sale of 4,700 common shares via Fidelity with an aggregate market value of $35,650.91 to be sold approximately on 09/02/2025 on the NYSE.

How were the shares being sold by the TDOC insider acquired?

The shares were acquired on 08/29/2025 through restricted stock vesting and the consideration is listed as compensation.

Did the filer recently sell other Teladoc shares?

Yes. The filing discloses a sale of 4,653 shares on 06/02/2025 for gross proceeds of $31,919.58 by Kelly Bliss.

How many Teladoc shares were reported outstanding in the filing?

The filing lists 176,690,662 shares outstanding.

Which broker is handling the proposed sale?

The broker named is Fidelity Brokerage Services LLC with an address at 900 Salem Street, Smithfield, RI; the sale is to occur on the NYSE.
Teladoc Health Inc

NYSE:TDOC

TDOC Rankings

TDOC Latest News

TDOC Latest SEC Filings

TDOC Stock Data

1.32B
175.39M
0.99%
74.28%
13.03%
Health Information Services
Services-offices & Clinics of Doctors of Medicine
Link
United States
NEW YORK